Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share repurchase of 22,600 H shares on 11 May 2026 via on-market transactions on the Hong Kong Stock Exchange.

The buyback was executed within a price range of HK$31.86 to HK$32.30 per share, with a volume-weighted average repurchase price of HK$32.09. The total consideration amounted to HK$0.73 million.

Following the transaction, HANXBIO-B’s issued share capital (excluding treasury shares) decreased from 135.69 million to 135.67 million shares, representing a 0.02% reduction. Treasury shares increased to 547,300, while the overall issued share count remained unchanged at 136.22 million shares.

The repurchase forms part of the mandate approved by shareholders on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative repurchases under this mandate now total 547,300 shares, equivalent to 0.40% of the company’s issued share capital on the mandate date.

In line with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on new share issues, sales or transfers of treasury shares until 10 June 2026.